CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Intracalvaria bone marrow injection +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05849805
NCT05849805N/ACompleted
CompareCT.gov

The Feasibility, Safety and Efficacy of Y-3 Injection Through Skull Bone Marrow Bypassing Blood-brain Barrier in the Treatment of Acute Malignant Middle Cerebral Artery Infarction(SOLUTION)

Beijing Tiantan Hospital·interventional·Posted May 9, 2023·Updated Apr 26, 2024

In Brief

A clinical study evaluating Intracalvaria bone marrow injection and Conventional treatment for Stroke, Acute Ischemic. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The mortality of malignant middle cerebral artery infarction (mMCAI) is up to 80%, while current available treatment is limited. The purpose of this study is to explore the feasibility, safety and efficacy of Intracalvaria bone marrow injection of cytoprotective drug Y-3 in mMCAI patients with contradictions of reperfusion therapy or poor reperfusion outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute Ischemic
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMay 9, 2023
Enrollment StartApr 17, 2023
Primary CompletionNov 6, 2023
Study CompletionJan 7, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.1 years ago

Interventions

Intracalvaria bone marrow injectionprocedure

Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days

Conventional treatmentother

standard treatment and management according to related guidelines